As Algeta's sibling, can Nordic Nanovector find the same success?
This article was originally published in Scrip
Executive Summary
Privately held cancer drug developer Nordic Nanovector – a spin-out company from the same founders who built Xofigo creator Algeta – is raising NOK150m ($25m) through a private placement of shares in order to progress development of its early-stage-blood cancer radio-immunotherapy, Betalutin. The CEO told Scrip that if all goes well, the company hopes to find a strategic partner and launch an IPO next year. However, there is a lot still to prove.
You may also be interested in...
Six New Molecules By 2030 – J&J’s Neuroscience Strategy
Can neuroscience be precise? Peter Fang, worldwide VP of neuroscience, explains J&J's approach to precision medicine in Alzheimer’s disease, depression and other neurological conditions.
Accessing Venture Debt From The EIB
Tips from Gergely Krajcsi, senior investment officer at the European Investment Bank, on how biotechs can access loans for faster growth.
In Vivo's 2024 Rising Leaders At A Glance
Top 30 leaders: see the list of industry influencers highlighted in the fifth edition of In Vivo's Rising Leaders series.